Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer

The aim of this study was to evaluate the efficacy, safety and tolerability of lobaplatin versus carboplatin as neoadjuvant therapy for stage II / III HER-2 positive breast cancer. Arms and Interventions Control group : Docetaxeor albumin paclitaxel combined with carboplatin for 6 cycles. Trastuzumab combined with pertuzumab : 6 cycles of treatment, according to the instructions recommended dosage. Experimental group : Docetaxel or albumin paclitaxel combined with lobaplatin for 6 cycles. Trastuzumab combined with pertuzumab : 6 cycles of treatment, according to the instructions recommended dosage.

NCT Number	NCT07093931
Lead Sponsor	Shandong Cancer Hospital and Institute Collaborators: Cancer Hospital Chinese Academy of Medical Science
Conditions	Breast Cancer
Enrollment	468 participants
Start Date	2025-08-01
Primary Completion	2027-08-01 (estimated)
Study Completion	2030-08-01 (estimated)
Updated on ClinicalTrials.gov	2025-07-30